OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 04:55 UTC. Every row links to its source record.

TFPI tissue factor pathway inhibitor

ENSG00000003436 · protein coding · Open Targets profile

Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma. .

3 of the 4 drugs recorded against TFPI are approved

Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.

2 antibody drugs at Approved: CONCIZUMAB, MARSTACIMAB1 protein drug at Approved: ANDEXANET ALFA1 unknown drug at Phase 2: BAY-1093884Antibody 2Protein 1Unknown 1Approved 3Phase 2 1

Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.

In 3 of 15 cancers, the evidence for TFPI comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751basal cell carcinomabasal cell carcinomabasal cell carcinoma: germline 0.20breast cancerbreast cancerbreast cancer: germline 0.14breast carcinomabreast carcinomanon-small cell lung carcinomanon-small cell lung carcinomaB-cell chronic lymphocytic leukemiaB-cell chronic lymphocytic leukemiainvasive breast carcinomainvasive breast carcinomacervical carcinomacervical carcinomacervical carcinoma: germline 0.12hepatocellular carcinomahepatocellular carcinomaprostate cancerprostate cancerFamilial prostate cancerFamilial prostate cancerprostate carcinomaprostate carcinomathyroid gland papillary carcinomathyroid gland papillary carcinomaovarian carcinomaovarian carcinomaneurocutaneous melanocytosisneurocutaneous melanocytosisessential thrombocythemiaessential thrombocythemia

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Antibody
Advanced Clinical, GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
PROTAC
Database Ubiquitination, Half-life Data, Small Molecule Binder
Other modalities
Approved Drug

gnomAD loss of function constraint: o/e 0.4329400062561035 (upper bound 0.6666499972343445). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

Principal investigators and study chairs on 12 registry trials, updated in the last three years, of the most advanced drugs against TFPI (concizumab, andexanet alfa, marstacimab, BAY-1093884), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.

2 of 11 trials of drugs against TFPI have sites only in Europe

Registry trials of concizumab, andexanet alfa, marstacimab, BAY-1093884 updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 2 of 11 have all sites in one country.

Sites only in this groupSites here and elsewhere
United StatesUnited States: 1 trials with sites only hereUnited States: 8 trials with sites here and elsewhere9ChinaChina: 0 trials with sites only hereChina: 3 trials with sites here and elsewhere3EuropeEurope: 2 trials with sites only hereEurope: 7 trials with sites here and elsewhere9JapanJapan: 0 trials with sites only hereJapan: 6 trials with sites here and elsewhere6OtherOther: 0 trials with sites only hereOther: 8 trials with sites here and elsewhere8

Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 1 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.

6 trials of drugs against TFPI were stopped early

Terminated, withdrawn and suspended interventional trials of concizumab, andexanet alfa, marstacimab, BAY-1093884, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 6 most recent of 6.

  • Ph3NCT05926349briefwhy it stopped
    withdrawn · 2024-10-26 · AstraZeneca · Andexanet alfa
    “Business decision”
  • Ph2NCT03330457briefwhy it stopped
    terminated · 2023-08-08 · Portola Pharmaceuticals · Andexanet alfa (bolus), Andexanet alfa (infusion IV)
    “Ended prematurely”
  • Ph2NCT04233073briefwhy it stopped
    terminated · 2023-03-22 · Alexion Pharmaceuticals, Inc. · andexanet alfa
    “Limited value as a single-arm study”
  • Ph1NCT04832139briefwhy it stopped
    terminated · 2022-07-11 · Pfizer · Marstacimab PFP, Marstacimab PFS
    “The study was terminated due to a change in the benefit/risk assessment for the further administration of marstacimab in a healthy volunteer population.”
  • Ph2NCT03597022briefwhy it stopped
    terminated · 2020-11-30 · Bayer · matched by the registry's drug synonyms
    “Due to thrombosis”
  • Ph1NCT03996486briefwhy it stopped
    withdrawn · 2019-10-22 · Bayer · matched by the registry's drug synonyms
    “Company decision”
Paediatric incentives and obligations for TFPI's drugs

For concizumab, andexanet alfa, marstacimab, BAY-1093884: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.

  • FDA pediatric target list: no · TFPI is not on the list
    Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
  • EU paediatric investigation plan: yes · EMA/PE/0000226246 (marstacimab, Treatment of congenital haemophilia A;Treatment of congenital haemophilia B): PM: decision on the application for modification of an agreed PIP, 28 Jan 2025; EMEA-002326-PIP04-20-M01 (concizumab, Treatment of congenital haemophilia A;Treatment of congenital haemophilia B): PM: decision on the application for modification of an agreed PIP, 8 Sept 2023; EMEA-001902-PIP01-15-M04 (andexanet alfa, Prevention of factor Xa inhibitor associated haemorrhage;Treatment of factor Xa inhibitor associated haemorrhage): PM: decision on the application for modification of an agreed PIP, 9 Sept 2020
    Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
  • EU orphan designation: yes · EU/3/23/2866 withdrawn 13 Dec 2023: Treatment of haemophilia B; EU/3/17/1940 withdrawn 12 Oct 2017: Treatment of haemophilia B; EU/3/12/1052 withdrawn 10 Oct 2012: Treatment of haemophilia A
    Rule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
  • Authorised in the EU: yes · Hympavzi: authorised since 18 Nov 2024; Ondexxya: authorised since 26 Apr 2019, conditional; Alhemo: authorised since 13 Dec 2024
    Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
  • FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link
    Rule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
  • FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of concizumab, andexanet alfa, marstacimab, bay-1093884
    Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
  • Registered studies open to children: yes · 9 interventional studies of concizumab, andexanet alfa, marstacimab, bay-1093884 include patients under 18; 7 are recruiting, not yet recruiting or active
    Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12

Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs

All 4 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
CONCIZUMABAntibodyapprovalhemorrhage, hemophilia B, hemophilia AOpen Targets · ChEMBL
ANDEXANET ALFAProteinapprovalhemorrhagic disease, intracranial hemorrhageOpen Targets · ChEMBL
MARSTACIMABAntibodyapprovalhemorrhage, hemophilia B, hemophilia A, hemophiliaOpen Targets · ChEMBL
BAY-1093884Unknownphase 2hemophilia B, hemophilia A, hemophiliaOpen Targets · ChEMBL